These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 1644290)

  • 1. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants.
    Mukherjee B; Morgenbesser SD; DePinho RA
    Genes Dev; 1992 Aug; 6(8):1480-92. PubMed ID: 1644290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation.
    Mäkelä TP; Koskinen PJ; Västrik I; Alitalo K
    Science; 1992 Apr; 256(5055):373-7. PubMed ID: 1566084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal levels of max are sufficient for the cotransformation of C3H10T1/2 cells by ras and myc.
    Davenport EA; Taparowsky EJ
    Exp Cell Res; 1992 Oct; 202(2):532-40. PubMed ID: 1397104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells.
    Barrett J; Birrer MJ; Kato GJ; Dosaka-Akita H; Dang CV
    Mol Cell Biol; 1992 Jul; 12(7):3130-7. PubMed ID: 1620120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
    Hurlin PJ; Ayer DE; Grandori C; Eisenman RN
    Cold Spring Harb Symp Quant Biol; 1994; 59():109-16. PubMed ID: 7587059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc.
    Desbarats L; Gaubatz S; Eilers M
    Genes Dev; 1996 Feb; 10(4):447-60. PubMed ID: 8600028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max.
    Gu W; Cechova K; Tassi V; Dalla-Favera R
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2935-9. PubMed ID: 8385351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MSSP promotes ras/myc cooperative cell transforming activity by binding to c-Myc.
    Niki T; Izumi S; Saëgusa Y; Taira T; Takai T; Iguchi-Ariga SM; Ariga H
    Genes Cells; 2000 Feb; 5(2):127-41. PubMed ID: 10672043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1.
    Lahoz EG; Xu L; Schreiber-Agus N; DePinho RA
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5503-7. PubMed ID: 8202517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.
    Ayer DE; Kretzner L; Eisenman RN
    Cell; 1993 Jan; 72(2):211-22. PubMed ID: 8425218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
    Hurlin PJ; Quéva C; Eisenman RN
    Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
    Min S; Taparowsky EJ
    Oncogene; 1992 Aug; 7(8):1531-40. PubMed ID: 1630816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic activity of the c-Myc protein requires dimerization with Max.
    Amati B; Brooks MW; Levy N; Littlewood TD; Evan GI; Land H
    Cell; 1993 Jan; 72(2):233-45. PubMed ID: 8425220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation.
    Reddy CD; Dasgupta P; Saikumar P; Dudek H; Rauscher FJ; Reddy EP
    Oncogene; 1992 Oct; 7(10):2085-92. PubMed ID: 1408152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).
    Kyo S; Takakura M; Taira T; Kanaya T; Itoh H; Yutsudo M; Ariga H; Inoue M
    Nucleic Acids Res; 2000 Feb; 28(3):669-77. PubMed ID: 10637317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteins.
    Billaud M; Isselbacher KJ; Bernards R
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2739-43. PubMed ID: 8464883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.